Showing results (101-110 of 120) with videos related to
Sort By:
Pageof 12
Journal of the European Academy of Dermatology and Venereology : JEADV|December 20, 2023
Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022G Pellacani, T Schlesinger, N Bhatia, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|July 13, 2021
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysisK Reich, U Mrowietz, A Menter, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 5, 2020
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)J Bagel, A Blauvelt, J Nia, et al.The British Journal of Dermatology|April 12, 2019
Continued treatment with secukinumab is associated with high retention or regain of responseM Augustin, D Thaci, K Eyerich, et al.The British Journal of Dermatology|June 13, 2020
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studiesA Blauvelt, C Paul, P van de Kerkhof, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 22, 2019
Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis RegistryP J Mease, J B Palmer, P Hur, et al.Journal of the American Academy of Dermatology|September 27, 2000
Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled studyA B Gottlieb, M Lebwohl, S Shirin, et al.Journal of the American Academy of Dermatology|March 1, 1991
A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasisE A Olsen, D L Cram, C N Ellis, et al.The British Journal of Dermatology|October 15, 2021
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasisK B Gordon, M Lebwohl, K A Papp, et al.The British Journal of Dermatology|April 8, 2021
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-upM Lebwohl, A Deodhar, C E M Griffiths, et al.Pageof 12